Arbutus Biopharma Corporation ABUS Restructuring Settlement And Impairment Provisions
Restructuring Settlement And Impairment Provisions at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:RestructuringSettlementAndImpairmentProvisions.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's restructuring settlement and impairment provisions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's restructuring settlement and impairment provisions?
- Arbutus Biopharma Corporation (ABUS) reported restructuring settlement and impairment provisions of $0 in Q1 2026.
- How has Arbutus Biopharma Corporation's restructuring settlement and impairment provisions changed year-over-year?
- Arbutus Biopharma Corporation's restructuring settlement and impairment provisions decreased by 100.0% year-over-year, from $2.81M to $0.
- What does restructuring settlement and impairment provisions mean?
- This captures non-recurring expenses related to organizational restructuring, legal settlements, or the impairment of assets. These provisions signal management's efforts to streamline operations or address significant liabilities. It is essential for identifying one-time charges that distort the underlying operational performance of the business.